FIECON

We look forward to sharing our research and presenting eight posters in Barcelona at #ISPOR EU 2024. Our research spans a variety of pressing topics in health economics and outcomes research, including the use of #AI, budget impact analyses, and frameworks for cost-effectiveness decision-making. HTA198 - Precedents for Reimbursed Highly Specialised Technologies Appraised By the National Institute for Health and Care Excellence: Key Takeaways and Recommendations HTA272 - Current Guidelines on the Use of Artificial Intelligence in Health Technology Assessments. EE144 - The Budget Impact of Cangrelor for the Treatment of Patients with Gastric Absorption Issues Undergoing Percutaneous Coronary Intervention in the UK. HTA163 - An Assessment of the Application of the NICE Severity Modifier. CO131 - Comparative efficacy of elafibranor and seladelpar in patients with primary biliary cholangitis: A network meta-analysis.   HTA119 - Assessing a potential framework to prioritise generalised cost-effectiveness analysis (#GCEA) value elements in future decision-making by evidence and relevance: case study across oncology and infectious diseases. EE611 - Cost-Effectiveness of Icosapent Ethyl in Patients with Recent Acute Coronary Syndrome in Catalonia. EE381 - Budget Impact of Icosapent Ethyl in Patients With Recent Acute Coronary Syndrome in Catalonia. Kudos to the FIECON abstract teams and co-authors for conducting the research and preparing the abstracts for submission. Yasmin Bappoo, Dhanveer Sandhu, Mark Burton, Will Wright, Amanda Hansson Hedblom , Amy Harris, Damian Kosinski, Marie Prett, Vicki Laskier-Owens, Emily Combe, Tom W., Harun Knight, Eva Istsenko, Chloe Teng, Laurence Tilley, Najida Begum, Susan Suponcic, Chetan Mistry, Sabine Gaugris, Caroline Barwood, Danielle Olivier, Fadel Shoughari, and Karl Freemyer, We eagerly anticipate the opportunity to share our findings and contribute to the vibrant discussions at ISPOR EU 2024 in Barcelona this November.

We're 'fired' up about our new B Corp plaque! Thank you Elvis & Kresse for sending us our B Corp plaque. Elvis & Kresse make luxury goods that showcase the beauty of reclaimed sustainable materials. Our plaque was crafted from a failed scaffolding board and the B Corp logo was made from a decommissioned British fire-hose - this thoughtful gift is a great example of their commitment to sustainability and community. We're grateful to be part of this community of businesses that share our values and commitment to making a positive impact. As a certified B Corp, we're dedicated to using business as a force for good, prioritising the well-being of people and the planet alongside profit. Thanks to everyone who's supporting us on this journey. #BCORP #Sustainability

AI analyses all data, humans decide what matters NICE - National Institute for Health and Care Excellence has just released a new position statement on the use of AI in evidence generation, emphasising on the following points. ‣ Transparency: AI methods should be clearly justified, with transparent reporting of their use, assumptions, and methodologies. The use of AI must be accessible to non-experts, with efforts to make complex models explainable. ‣ Validation: Robust validation is essential, including technical and external validation of AI methods. AI should be tested against other methods, and results should be presented with appropriate context and sensitivity analyses. ‣ Human Augmentation: AI should augment, not replace, human expertise. Human oversight is crucial, and AI use should be accompanied by a capable and informed human in the loop. FIECON’s team of AI experts pioneered an AI-driven systematic literature review (#SLR) workflow, fully aligned with the principles NICE outlined in their recent position statement—well before it was published. Our innovative approach boosts the efficiency of evidence generation while ensuring human expertise remains at the core. By prioritising rigorous validation and transparent reporting, our AI-SLR workflow not only meets but exceeds the stringent standards set by NICE. As HTA bodies increasingly embrace AI-driven processes, FIECON is uniquely positioned to lead this transformation in evidence generation. In FIECON, AI is never solely autonomous. To learn more about our AI-SLR workflow, check out our video here. https://lnkd.in/evenmdHv #AIinHealthcare #SLR #HTA #NICE

Balancing Act for Spanish HTA The new Spanish Health Technology Assessment (HTA) process has been designed to align with European Union regulations while retaining autonomy and flexibility. By integrating the Joint Clinical Assessment (JCA) framework into its national HTA process, Spain hopes to ensure timely and transparent evaluations. Read more about this balanced approach in this article (https://lnkd.in/eCdKjjRH) which explores how Spain's HTA process reflects a cautious yet collaborative attitude toward JCA regulation. #JCA #Lifesciencenews #HEOR #HTA

As the JCA framework becomes mandatory in 2025, pharmaceutical executives will face the challenge of navigating stringent timelines and diverse country-specific requirements. In our latest newsletter, FIECON's JCA experts outline how to anticipate and tackle these challenges. By combining strategic foresight with AI-assisted workflows, we will provide actionable insights to ensure a smooth and successful path to market access. #JCA #HEOR #HTA

Transform #JCA Challenges into Market Opportunities with FIECON’s Expertise   Navigating the Joint Clinical Assessment (JCA) framework for product launches might present you with significant hurdles. At FIECON, we understand the critical pain points that could impede your success: ◉ Limited Assessor Interaction: Lack of visibility into draft questions and minimal engagement during scoping phases. ◉ Multiple PICOs: Traditional approaches could overwhelm teams with numerous Potentially Important Clinical Outcomes (PICOs), leading to unmanageable workloads. ◉ Tight Timelines: A strict 100-day deadline to develop a dossier and gather all necessary evidence.   Meet FIECON’s AI-Powered PICO Prediction Tool. Our cutting-edge AI tool will anticipate PICOs by meticulously scanning databases, preprint libraries, and conference abstracts, ensuring you’re fully prepared before JCA PICOs are released. Here’s how we will streamline the process: ➔ PICO Survey: AI-driven prediction and identification of relevant PICOs. ➔ Consolidation: Drafting of preliminary PICOs based on AI insights. ➔ Validation: Refinement and finalization of PICOs with expert consultation. ➔ Final Dossier: Conducting Systematic Literature Reviews (SLRs) and Indirect Treatment Comparisons (ITCs) to develop and align your submission dossier. With FIECON, your submission will be expertly tailored to meet every requirement, fast-tracking your journey to market access. Uncover #EVERYTHING you always wanted to know about the #JCA on our website: https://lnkd.in/exqmxfEf and see how FIECON’s expertise will truly make a difference: https://lnkd.in/ef-G7jSn . #HEOR #MarketAccess #FIECONExperts #HTA

Welcome to the consultancy team - Stefano Perni PhD, MBA Director, HEOR and Access! https://lnkd.in/eguErA2H   Stefano brings a wealth of experience in #HEOR, with a particular strength in guiding clients through intricate market access challenges. His expertise shines in crafting decision analysis tools that adapt to rapidly evolving treatment landscapes, particularly in rare disease settings. Stefano has also been at the forefront of securing reimbursement for ground breaking therapies, including CAR-Ts, immunotherapies, and targeted treatments.   Driven by a passion for using HEOR to enhance patient outcomes, Stefano expertly combines medical science, and economics with cutting-edge approaches. As he joins our dynamic team, Stefano is poised to advance our mission of delivering tailored HEOR and market access solutions to our clients.   As we continue to grow, we're excited to welcome ambitious professionals to our team by filling key Manager-level positions. If you’re ready to make an impact in the field of HEOR and market access, get in touch with Nawale Benghrib to learn more.   #WelcomeToTheTeam #HEOR #MarketAccess

We have our very own new private large language model! FIECON Lab has developed a new private LLM platform to provide our team with advanced AI-assisted capabilities. This innovative LLM platform is a revolution in human AI-assisted consulting, accelerating how we share knowledge and best practices within FIECON and significantly enhancing our capabilities, with a prudent eye trained on responsible stewardship. The LLM platform resides locally within the FIECON network and is based on proprietary industry-specific knowledge, publicly available resources (like HTA guidelines or reports), and our in-house processes which support the consultancy team. FIECON LLM delivers: 🔴 A best practice hub for FIECON’s in-house consultancy expertise and knowledge. 🔴 A secure and transparent platform that operates within strict boundaries, ensuring client data is never used in the model training process, thereby maintaining confidentiality. 🔴 A bespoke solution tailored to our industry, understanding our life science lexicon. 🔴 Automation of high-intensity tasks that require manual curation, opening up capacity and headspace for the strategic thinking and human-added value that our clients expect and value from FIECON. 🔴 AI sensitivity with human specificity as a major benefit for our clients who can expect exceptional, strategic support delivered 100% by humans (with AI assistance). 🔴 A cornerstone to our existing digital offerings (e.g. Model Builder, AI-assisted SLR, Outcomes analyzer, NMA builder, and more). Comment below on your techno-optimism for human AI-assisted consulting, and share your ideas on how we can apply this to be better than ever for our customers and the broader patient/provider/payer ecosystem!

PICOS prediction is going to be critical to meeting JCA timelines. Really cool idea

Will your next EU product launch face tight deadlines with the #JCA?    Following the video explaining the Joint Clinical Assessment (JCA) process, Amanda Hansson Hedblom, FIECON's JCA expert, delves into the primary challenges posed by the upcoming JCA process starting in January 2025. The varying impact on member states and the tight 100-day timeline for dossier submission are significant hurdles. Watch the video to understand how FIECON’s innovative "PICO Prediction" approach, leveraging AI and local expertise, prepares you to meet these challenges head-on by anticipating likely relevant #PICOs and streamlining the preparation process.   Video Highlights: 00:00 Challenges with the JCA 1: Geographical variation 00:37 EU HTA member states' differing attitudes towards mandatory joint HTA 00:53 Challenges with the JCA 2: Tight timeline 01:25 FIECON's Solution   Discover more key insights from the full interview here: https://lnkd.in/eVtp7cbU and stay tuned for more JCA updates from FIECON.   #HealthEconomics #HTA #FIECON #AI